Study: Blocking inflammatory pathway could prevent melanoma brain metastasis

Reviewed by James Ives, M.Psych. (Editor)Aug 20 2019

Brain metastases are among the deadliest tumor metastases, with a median survival period of less than one year, and the incidence of brain metastasis is rising.

A new Tel Aviv University study finds that melanoma brain metastasis occurs when tumor cells "hijack" an inflammatory pathway in the brain. Blocking this pathway could prevent these metastases from developing, according to the research.

The prognosis of patients with brain metastases is very grim. Patients used to die from metastases in other places before brain metastases were clinically evident. Treatments have improved and patients are living longer, so the incidence of diagnosed brain metastases is increasing. Understanding how and why brain metastasis occurs is an urgent challenge facing cancer researchers today."

Prof. Neta Erez, lead author of the study, Department of Pathology at TAU's Sackler Faculty of Medicine

The research was published in Cell Reports on August 13. It was conducted by TAU graduate students Dr. Hila Doron and Malak Amer, in collaboration with Prof. Ronit Satchi-Fainaro, also of TAU's Sackler Faculty of Medicine.

The new research focuses on melanoma brain metastasis because "melanoma is the deadliest skin cancer due to its high rate of metastasis, frequently to the brain," says Prof. Erez.

The scientists utilized a mouse model of spontaneous melanoma brain metastasis to study the interactions of melanoma tumors within the brain microenvironment. They discovered that melanoma brain metastasis is facilitated by the takeover of a physiological inflammatory pathway by astrocytes, the brain cells that maintain a protected environment in the brain. In addition, astrocytes respond to tissue damage in the brain by instigating an inflammatory and tissue repair response to contain the damage, secreting inflammatory factors that recruit immune cells.

"We discovered that tumor cells recruit these inflammatory factors to hijack their way to the brain," says Prof. Erez. "We identified a specific factor that mediates their attraction to the brain and showed that brain metastasizing melanoma cells express the receptor for the inflammatory factor, which is how they respond to this signal."

Significantly, when the researchers used genetic tools to inhibit the expression of the receptor on melanoma cells, they successfully blocked the ability of tumor cells to respond to astrocyte signaling -- and the development of brain metastases was significantly inhibited.

After the initial research was performed in a pre-clinical mouse model, the scientists validated their results in the brain metastases of patients who had undergone brain surgery, finding that astrocytes express the same inflammatory factor (CXCL10) and that the tumor cells express the same receptor (CXCR3) as the mouse model. This suggests that the identical mechanism is operative in humans.

"Our findings suggest that blocking this signaling pathway may prevent brain metastasis," concludes Prof. Erez. "The CXCL10-CXCR3 axis may be a potential therapeutic target for prevention of melanoma brain metastasis."

The researchers are currently investigating the trigger that instigates inflammation in the brain, which promotes metastasis.